Phd Candidate, Chemical Engineer


Eva-Alexandra Salvanou is a PhD candidate working on Nuclear Medicine in conjunction with Nanomedicine at the Radiochemical Studies Laboratory of the Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety of NCSR “Demokritos”, since November 2017.

Having graduated with a Master’s Degree in Chemical Engineering from the National Technical University of Athens (NTUA), she continued implementing the knowledge gained, by starting a doctorate’s degree at the School of Pharmacy of the University of Patras. Her research focuses on the radiolabeling of nanoparticles for theragnostic purposes on the oncology field. Her professional career at the Radiochemical Studies Laboratory includes working with different isotopes (67Ga, 68Ga, 177Lu, 225Ac, 99mTc), and various nanostructures (e.g. iron, gold). Experience with cell cultures and cytotoxicity assays has been gained as well as knowledge and hands-on experience on laboratory animals not only by acquiring the FELASA accredited Course 056/16 (6th Laboratory Animal Science European Union Functions Course (Functions A,B,C,D)) but also by performing in vivo experiments for her research project.

Selected Grants

COST Action CA19114: Network for Optimized Astatine labeled Radiopharmaceuticals

2020-2024 | European Cooperation in Science and Technology (COST)

The purpose of the COST Action CA19114 entitled "Network for Optimized Astatine-labeled Radiopharmaceuticals" (NOAR) is to create a network of scientists to investigate the production conditions of the α-particle emitter Astatine-211 (Astatine-211: 211At) and its application in Targeted A...


COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside"

2018-2022 | European Cooperation in Science and Technology (COST)

The COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside" focuses on the development of nanosystems transporting anti-cancer drugs. The pan-European network of specialists from universities, research centers, clinical research organizations and companies is ...


Dual-targeting iron oxide nanoparticles against bombesin receptors (BNRs) and Prostate Specific Membrane Antigen (PSMA), radiolabeled with Gallium-68, as PET/MRI imaging agents for prostate cancer

2020-2021 | ΕΣΠΑ/Εκπαίδευση και Δια Βίου Μάθηση

The present research project is focused on the development of iron oxide nanoparticles (IONPs) radiolabeled with 68Ga, for dual-modality molecular imaging of prostate cancer with PET/MRI. These NPs are functionalized with adequate pharmacophores (peptides or peptidomimetic molecules) so a...

INRASTES - Official Web Site
Skip to content